Published in Cancer Immunol Res on August 29, 2017
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med (2011) 4.71
Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med (2005) 4.10
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
CD8+ T cell efficacy in vaccination and disease. Nat Med (2008) 3.20
Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science (2001) 2.95
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J Immunol (2008) 2.42
How much TCR does a T cell need? Immunity (2001) 2.18
Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity (2006) 1.95
Requirements for peptide-induced T cell receptor downregulation on naive CD8+ T cells. J Exp Med (1997) 1.70
Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol (2007) 1.61
T cell-positive selection uses self-ligand binding strength to optimize repertoire recognition of foreign antigens. Immunity (2013) 1.58
In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest (2003) 1.54
Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol (2011) 1.47
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol (2005) 1.39
Serial TCR engagement and down-modulation by peptide:MHC molecule ligands: relationship to the quality of individual TCR signaling events. J Immunol (1999) 1.34
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination. Sci Transl Med (2015) 1.29
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol (2000) 1.18
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
The TCR's sensitivity to self peptide-MHC dictates the ability of naive CD8(+) T cells to respond to foreign antigens. Nat Immunol (2014) 1.12
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J Immunother (2009) 1.08
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res (2011) 1.06
Caveats in the design of MHC class I tetramer/antigen-specific T lymphocytes dissociation assays. J Immunol Methods (2003) 1.05
Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Semin Cancer Biol (2007) 1.01
Functional avidity: a measure to predict the efficacy of effector T cells? Clin Dev Immunol (2012) 1.01
T cell avidity determines the level of CTL activation. Eur J Immunol (2004) 0.90
Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies. Clin Transl Immunology (2014) 0.89
Control of T cell antigen reactivity via programmed TCR downregulation. Nat Immunol (2016) 0.87
Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol Immunother (2011) 0.84
T memory stem cells in health and disease. Nat Med (2017) 0.82
Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology (2014) 0.80
Cleavage of anti-apoptotic Bcl-2 family members after TCR stimulation contributes to the decision between T cell activation and apoptosis. J Immunol (2012) 0.80
Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy. J Clin Invest (2015) 0.78